{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:14:59Z","timestamp":1788052499322,"version":"build-2784847793"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119131","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:40:02Z","timestamp":1783528802000},"page":"119131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of a potent PROTAC targeting G9a suppresses proliferation of triple-negative breast cancer cells and psoriasis-like keratinocytes"],"prefix":"10.1016","volume":"318","author":[{"given":"Mingxia","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoping","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengbo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1536-8882","authenticated-orcid":false,"given":"Gu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119131_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/life11101082","article-title":"Structure, activity, and function of the protein lysine methyltransferase G9a","volume":"11","author":"Poulard","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.ejmech.2026.119131_bib2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nrd3674","article-title":"Epigenetic protein families: a new frontier for drug discovery","volume":"11","author":"Arrowsmith","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119131_bib3","doi-asserted-by":"crossref","first-page":"25309","DOI":"10.1074\/jbc.M101914200","article-title":"Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3","volume":"276","author":"Tachibana","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119131_bib4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nsmb.1384","article-title":"The ankyrin repeats of G9a and GLP histone methyltransferases are mono- and dimethyllysine binding modules","volume":"15","author":"Collins","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.119131_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173827","article-title":"Targeting EHMT2\/G9a for cancer therapy: progress and perspective","volume":"893","author":"Jan","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119131_bib6","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1101\/gad.1284005","article-title":"Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9","volume":"19","author":"Tachibana","year":"2005","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2026.119131_bib7","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/tcr.201800082","article-title":"Mechanisms and inhibitors of histone arginine methylation","volume":"18","author":"Fulton","year":"2018","journal-title":"Chem. Rec."},{"key":"10.1016\/j.ejmech.2026.119131_bib8","doi-asserted-by":"crossref","first-page":"41963","DOI":"10.1074\/jbc.M111.298463","article-title":"A distinct mechanism for coactivator versus corepressor function by histone methyltransferase G9a in transcriptional regulation","volume":"286","author":"Purcell","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119131_bib9","doi-asserted-by":"crossref","first-page":"19673","DOI":"10.1073\/pnas.1211803109","article-title":"G9a functions as a molecular scaffold for assembly of transcriptional coactivators on a subset of glucocorticoid receptor target genes","volume":"109","author":"Bittencourt","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.119131_bib10","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2017.05.015","article-title":"Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3","volume":"67","author":"Wei","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2026.119131_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108341","article-title":"G9a promotes breast cancer recurrence through repression of a pro-inflammatory program","volume":"33","author":"Mabe","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.119131_bib12","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.7150\/thno.23824","article-title":"G9a stimulates CRC growth by inducing p53 Lys373 dimethylation-dependent activation of Plk1","volume":"8","author":"Zhang","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2026.119131_bib13","doi-asserted-by":"crossref","first-page":"27857","DOI":"10.1074\/jbc.M109.000950","article-title":"The NF-kappaB factor RelB and histone H3 lysine methyltransferase G9a directly interact to generate epigenetic silencing in endotoxin tolerance","volume":"284","author":"Chen","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119131_bib14","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.chembiol.2023.09.012","article-title":"Non-canonical function of histone methyltransferase G9a in the translational regulation of chronic inflammation","volume":"30","author":"Muneer","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119131_bib15","doi-asserted-by":"crossref","first-page":"583","DOI":"10.21037\/atm-22-1884","article-title":"G9a promotes inflammation in Streptococcus pneumoniae induced pneumonia mice by stimulating M1 macrophage polarization and H3K9me2 methylation in FOXP1 promoter region","volume":"10","author":"Li","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.119131_bib16","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1053\/j.gastro.2022.10.011","article-title":"G9a modulates lipid metabolism in CD4 T cells to regulate intestinal inflammation","volume":"164","author":"Ramos","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2026.119131_bib17","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/s41467-018-03704-z","article-title":"Epigenetic control of IL-23 expression in keratinocytes is important for chronic skin inflammation","volume":"9","author":"Li","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119131_bib18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ejmech.2019.06.072","article-title":"Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents","volume":"179","author":"Cao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119131_bib19","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1021\/cb300139y","article-title":"A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma","volume":"7","author":"Yuan","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119131_bib20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.molcel.2007.01.017","article-title":"Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase","volume":"25","author":"Kubicek","year":"2007","journal-title":"Mol Cell"},{"key":"10.1016\/j.ejmech.2026.119131_bib21","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nchembio.599","article-title":"A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells","volume":"7","author":"Vedadi","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119131_bib22","doi-asserted-by":"crossref","first-page":"8931","DOI":"10.1021\/jm401480r","article-title":"Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP","volume":"56","author":"Liu","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119131_bib23","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1021\/acs.jmedchem.2c02059","article-title":"Discovery of novel substrate-competitive lysine methyltransferase G9a inhibitors as anticancer agents","volume":"66","author":"Nishigaya","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119131_bib24","doi-asserted-by":"crossref","first-page":"10506","DOI":"10.1021\/acs.jmedchem.2c00652","article-title":"Discovery of the first-in-class G9a\/GLP covalent inhibitors","volume":"65","author":"Park","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119131_bib25","doi-asserted-by":"crossref","first-page":"115841","DOI":"10.1016\/j.ejmech.2023.115841","article-title":"Discovery of novel G9a\/GLP covalent inhibitors for the treatment of triple-negative breast cancer","volume":"261","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119131_bib26","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1021\/acs.jmedchem.4c02781","article-title":"Current and emerging approaches targeting G9a for the treatment of various diseases","volume":"68","author":"He","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119131_bib27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119131_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103395","article-title":"PROTAC technology: a new drug design for chemical biology with many challenges in drug discovery","volume":"28","author":"Guedeney","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.119131_bib29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cbf.3369","article-title":"The PROTAC technology in drug development","volume":"37","author":"Zou","year":"2019","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.ejmech.2026.119131_bib30","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1039\/D4MD00142G","article-title":"Recent insights of PROTAC developments in inflammation-mediated and autoimmune targets: a critical review","volume":"15","author":"Galla","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119131_bib31","doi-asserted-by":"crossref","first-page":"5844","DOI":"10.1021\/jm100478y","article-title":"Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines","volume":"53","author":"Liu","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119131_bib32","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nsmb.1560","article-title":"Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294","volume":"16","author":"Chang","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.119131_bib33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40164-024-00554-y","article-title":"Epigenetic alterations of TP53INP1 by EHMT2 regulate the cell cycle in gastric cancer","volume":"13","author":"Ryu","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119131_bib34","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.bbrc.2018.01.074","article-title":"EHMT2 is a metastasis regulator in breast cancer","volume":"496","author":"Kim","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2026.119131_bib35","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.3892\/ol.2014.2034","article-title":"Modulation of microRNA expression in human lung cancer cells by the G9a histone methyltransferase inhibitor BIX01294","volume":"7","author":"Pang","year":"2014","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ejmech.2026.119131_bib36","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1021\/acs.jmedchem.6b01645","article-title":"Discovery of potent and selective inhibitors for G9a-Like protein (GLP) lysine methyltransferase","volume":"60","author":"Xiong","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119131_bib37","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nsmb.1560","article-title":"Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294","volume":"16","author":"Chang","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.119131_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113749","article-title":"Developments of CRBN-based PROTACs as potential therapeutic agents","volume":"225","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119131_bib39","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1039\/D2CS00387B","article-title":"Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders","volume":"51","author":"Diehl","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.119131_bib40","doi-asserted-by":"crossref","first-page":"244","DOI":"10.15212\/AMM-2022-0010","article-title":"PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective","volume":"1","author":"Han","year":"2022","journal-title":"Acta materia medica"},{"key":"10.1016\/j.ejmech.2026.119131_bib41","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1080\/14756366.2022.2074414","article-title":"Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents","volume":"37","author":"Wang","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119131_bib42","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","article-title":"Targeted protein degradation: from mechanisms to clinic","volume":"25","author":"Tsai","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119131_bib43","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrm1621","article-title":"IAPs, RINGs and ubiquitylation","volume":"6","author":"Vaux","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119131_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103395","article-title":"PROTAC technology: a new drug design for chemical biology with many challenges in drug discovery","volume":"28","author":"Guedeney","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.119131_bib45","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1039\/D2CS00220E","article-title":"Chemistries of bifunctional PROTAC degraders","volume":"51","author":"Cao","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.119131_bib46","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119131_bib47","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1039\/C0MB00074D","article-title":"Impact of linker length on the activity of PROTACs","volume":"7","author":"Cyrus","year":"2011","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.ejmech.2026.119131_bib48","doi-asserted-by":"crossref","first-page":"381","DOI":"10.37349\/etat.2020.00023","article-title":"Novel approaches for the rational design of PROTAC linkers","volume":"1","author":"Zagidullin","year":"2020","journal-title":"Explor Target Antitumor Ther."},{"key":"10.1016\/j.ejmech.2026.119131_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.pep.2021.106012","article-title":"Linkers: a synergistic way for the synthesis of chimeric proteins","volume":"191","author":"Patel","year":"2022","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.ejmech.2026.119131_bib50","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1021\/acs.orglett.5b02375","article-title":"One-step synthesis of 2-Chloropyrimidin-4-ol derivatives: an unusual reactivity of thiophosgene","volume":"17","author":"Callingham","year":"2015","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2026.119131_bib51","doi-asserted-by":"crossref","first-page":"11353","DOI":"10.1016\/j.ejmech.2021.113645","article-title":"Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation","volume":"223","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119131_bib52","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1021\/acs.jmedchem.0c02234","article-title":"Design and synthesis of EZH2-Based PROTACs to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119131_bib53","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1016\/j.apsb.2024.04.007","article-title":"Characteristic roadmap of linker governs the rational design of PROTACs","volume":"14","author":"Dong","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119131_bib54","article-title":"Targeting G9a exerts pleiotropic suppression in triple-negative breast cancer cells: cooperatively inducing pyroptosis and apoptosis","volume":"16","author":"Li","year":"2026","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2026.119131_bib55","first-page":"6","article-title":"MG132, a proteasome inhibitor, induces apoptosis in tumor cells, Asia Pac","volume":"9","author":"Guo","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119131_bib56","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1021\/acs.jmedchem.3c01468","article-title":"Discovery of novel PROTAC degraders of p300\/CBP as potential therapeutics for hepatocellular carcinoma","volume":"67","author":"Chang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119131_bib57","article-title":"A degron blocking strategy towards improved CRL4(CRBN) recruiting PROTAC selectivity","volume":"24","author":"Bouguenina","year":"2023","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2026.119131_bib58","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","article-title":"Lessons in PROTAC design from selective degradation with a promiscuous warhead","volume":"25","author":"Bondeson","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119131_bib59","doi-asserted-by":"crossref","DOI":"10.1126\/science.aat0572","article-title":"Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN","volume":"362","author":"Sievers","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119131_bib60","doi-asserted-by":"crossref","first-page":"14513","DOI":"10.1021\/acs.jmedchem.3c00851","article-title":"Leveraging ligand affinity and properties: discovery of novel benzamide-type cereblon binders for the design of PROTACs","volume":"66","author":"Steinebach","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119131_bib61","doi-asserted-by":"crossref","first-page":"19280","DOI":"10.1074\/jbc.M602257200","article-title":"Catalytic roles for carbon-oxygen hydrogen bonding in SET domain lysine methyltransferases","volume":"281","author":"Couture","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119131_bib62","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1080\/07391102.2018.1491422","article-title":"Delineating the active site architecture of G9a lysine methyltransferase through substrate and inhibitor binding mode analysis: a molecular dynamics study","volume":"37","author":"Ramya Chandar Charles","year":"2019","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejmech.2026.119131_bib63","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jsb.2014.10.010","article-title":"Thalidomide mimics uridine binding to an aromatic cage in cereblon","volume":"188","author":"Hartmann","year":"2014","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.ejmech.2026.119131_bib64","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1021\/jacsau.4c00831","article-title":"Structure-based design of \"Head-to-Tail\" macrocyclic PROTACs","volume":"4","author":"Li","year":"2024","journal-title":"JACS Au"},{"key":"10.1016\/j.ejmech.2026.119131_bib65","article-title":"EHMT2 inhibition induces cell death in human non-small cell lung cancer by altering the cholesterol biosynthesis pathway","volume":"21","author":"Kim","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119131_bib66","article-title":"The selective activation of p53 target genes regulated by SMYD2 in BIX-01294 induced autophagy-related cell death","volume":"10","author":"Fan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119131_bib67","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/imm.13680","article-title":"cAMP responsive element modulator \u03b1 promotes effector T cells in systemic autoimmune diseases","volume":"170","author":"Carlsson","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.ejmech.2026.119131_bib68","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41419-023-06134-y","article-title":"Depletion of G9A attenuates imiquimod-induced psoriatic dermatitis via targeting EDAR-NF-\u03baB signaling in keratinocyte","volume":"14","author":"Fang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2026.119131_bib69","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the pathogenesis of psoriasis: from keratinocyte perspective","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2026.119131_bib70","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.4314\/tjpr.v21i6.11","article-title":"Bergenin attenuates TNF-\u03b1-induced oxidative stress and inflammation in HaCaT cells by activating Nrf2 pathway and inhibiting NF-\u03baB pathway","volume":"21","author":"Ye","year":"2022","journal-title":"Trop. J. Pharmaceut. Res."},{"key":"10.1016\/j.ejmech.2026.119131_bib71","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"van der Fits","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2026.119131_bib72","doi-asserted-by":"crossref","first-page":"21400","DOI":"10.1021\/acs.jmedchem.4c02318","article-title":"Discovery of novel N-Sulfonamide-tetrahydroquinolines as potent retinoic acid receptor-related orphan receptor \u03b3t (ROR\u03b3t) inverse agonists for the treatment of psoriasis","volume":"67","author":"Lv","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119131_bib73","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.119131_bib74","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2004.04.012","article-title":"Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment","volume":"51","author":"Langley","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejmech.2026.119131_bib75","first-page":"1847","article-title":"Establishment of psoriasis mouse model by imiquimod","volume":"52","author":"Que","year":"2025","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ejmech.2026.119131_bib76","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jdermsci.2012.11.002","article-title":"NF-\u03baB: an essential transcription factor in psoriasis","volume":"69","author":"Goldminz","year":"2013","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.ejmech.2026.119131_bib77","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1172\/JCI11914","article-title":"Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer","volume":"107","author":"Yamamoto","year":"2001","journal-title":"J. Clin. Investig."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:22:28Z","timestamp":1788049348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426005763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":77,"alternative-id":["S0223523426005763"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119131","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a potent PROTAC targeting G9a suppresses proliferation of triple-negative breast cancer cells and psoriasis-like keratinocytes","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119131","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119131"}}